Pertussis Maternal Immunization Study

Condition(s) targeted: Pregnant Women

Intervention: Tdap (Biological); Td (Biological)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: Dalhousie University

Official(s) and/or principal investigator(s):
Scott A Halperin, MD, Principal Investigator, Affiliation: Dalhousie Univeristy - Canadian Center for Vaccinology

Overall contact:
Beth A Halperin, MN, Phone: 902-470-8992, Email: bhalperin@nb.aibn.com

The purpose of this study is to assess whether immunization against pertussis in the mid third trimester of pregnancy provides passive protection to the infant by transfer of IgG transplacentally and by transfer of secretory IgA (and possibly IgG) in breast milk, sufficient to protect the infant against pertussis disease in the critical neonatal period, without suppressing the infant's immune response to active immunization and disease

Official title: Immunization of Women With Diphtheria and Tetanus Toxoids Combined With Acellular Pertussis (Tdap) During the Mid Third Trimester of Pregnancy: An Evaluation of the Potential for Immunological Protection for the Neonate

Study design: Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Comparison of serum IgG antibody levels against PT, FHA, PRN, FIM between Tdap and Td groups

Secondary outcome: Safety of Tdap in pregnancy including pregnancy outcome and developmental assessment.

Detailed description: The purpose of this study is to assess the potential of providing initial immunological protection to the neonate by providing passive placentally transferred serum antibodies and breast milk antibodies against pertussis antigens (PT, FHA, PRN, FIM). This will be accomplished by

- determining the rate of maternal antibody decline from time of immunization until 12

months postpartum by measuring antibody levels in serum, saliva, and breast milk at specified intervals;

- determining levels of antibody transferred to the neonate relative to the interval from

immunization to delivery;

- comparing levels of transplacentally transferred antibody with those achieved after the

first, second, and third dose of the primary immunization series; and

- determining whether maternal immunization interferes with active antibody production

following licensed DTaP-IPV-Hib in infants of women immunized during the mid third trimester of pregnancy.

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Pregnant women 18-45 years of age.

- Women who, at ≥30-<32 weeks gestation, are at low risk for complications as

determined by the obstetrical algorithm for identification of eligible subjects and the obstetrical risk assessment form.

- Signed, informed consent.

Exclusion Criteria:

- Failure to meet eligibility criteria as determined by the obstetrical algorithm for

identification of eligible subjects and the obstetrical risk assessment form.

- History of significant medical disorder (such as bleeding disorders, cancer,

autoimmune disease, immunodeficiency (including HIV-infected individuals, transplant recipients), seizure disorder or significant psychiatric illness, drug or alcohol dependence).

- Receipt of any high-dose daily corticosteroids (inhaled steroids are acceptable)

within 2 weeks of study entry. High dose is defined as a dose of ≥20 mg of prednisone daily or equivalent.

- History of physician-diagnosed or laboratory-confirmed pertussis within the past 5

years.

- Personal history (verbal or documented) of ever having received Tdap.

- Personal history (verbal or documented) of having received Td immunization within the

past 2 years.

- History of febrile illness (>37. 8ºC orally) within the past 72 hours (immunization

may be deferred).

- History of sensitivity to any component of Tdap.

- Receipt of blood products or immunoglobulin within 3 months of study entry (except

RH-negative women who receive immunoglobulin during pregnancy are eligible).

- Receipt of any vaccines within 2 weeks of study vaccine (except influenza vaccine

which may be given concurrently).

- Failure to give written, informed consent.

Beth A Halperin, MN, Phone: 902-470-8992, Email: bhalperin@nb.aibn.com

Clinical Trial Research Center - Canadian Center for Vaccinology, Halifax, Nova Scotia B3K 6R8, Canada; Recruiting
Beth A Halperin, MN, Phone: 902-470-8992, Email: bhalperi@nb.aibn.com
Pam D MacIntyre, RN, Phone: 902-470-8948, Email: pamela.macintyre@iwknshealth.ca

Canadian Center for Vaccinology Home Page

Starting date: November 2007
Last updated: August 30, 2010